We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biomarkers – Products

SureSeq™ Myeloid MRD Panel box.
Product News

OGT to Premiere SureSeq™ Myeloid MRD Panel for AML Disease Monitoring at AMP

New NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples.
Cancer cells.
Product News

Xsphera Biosciences and NEX-I Collaborate To Advance Oncology Drug Research

Xsphera Biosciences, is pleased to announce the formalization of a Memorandum of Understanding (MOU) with NEX-I, a Seoul-based pioneer in immune-oncology therapeutics.
A doctor holding a clipboard with a patient.
Product News

OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.
An outsretched palm holding an assortment of different pills.
Product News

PharmaKure Submits Mhra CTA for Phase 2a Clinical Trial of PK051 in Patients With Mild Cognitive Impairment

Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.
A scientist holding up a 96-well plate.
Product News

PharmaKure Announces Study Success for Novel Blood Test To Identify Biomarkers in Patients With Alzheimer’s Disease

Study confirms ALZmetrixTM whole blood test can detect people at high risk of developing full Alzheimer’s Disease.
Cancer Cell Target
App Note / Case Study

Discover the Future of Cancer Research With Whole-Genome Sequencing

To accelerate the discovery of new cancer biomarkers and new insights into the genetics of treatment-resistant tumors, it is crucial to gain a deeper understanding of the genomic and epigenomic variations in cancer.
A scientist holding a rack of blood samples.
Product News

Sebia Launches M-InSight®, a Test for Monitoring Multiple Myeloma Patients

Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma.
A microarray result.
Product News

Sengenics Corporation Launches I-Ome Discovery To Advance Immune Biomarker Discovery and Development

Microarray-based solution enables deeper investigations of the humoral immune response in disease biology.
Sensitive Bioanalysis of Biomarkers in Cerebral Spinal Fluid
App Note / Case Study

Enhancement of Sensitive Bioanalysis of Biomarkers in Cerebral Spinal Fluid

This app note highlights a highly sensitive method developed for the detection of GalSPH and GluSPH in CSF.

Reagents
Whitepaper

Get the Latest Clinical Insights for Tumor Exome Profiling

This whitepaper explores the latest reagents and software available to enhance tumor exome profiling for the generation of accurate, actionable clinical insights.

Advertisement